Agios Pharmaceuticals (AGIO) Earns Media Impact Rating of 0.17
Media stories about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.0847300836257 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Diehard Bargain Hunter: Forum Energy Technologies, Inc. (FET), Agios Pharmaceuticals, Inc. (AGIO) – AllStockNews (allstocknews.com)
- These business leaders have resigned from President Trump’s special council (fishinghd.com)
- See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. (finance.yahoo.com)
- Agios Pharmaceuticals Inc (AGIO) RMI Running Higher in Consecutive Sessions – Evergreen Caller (evergreencaller.com)
- Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y – Nasdaq (nasdaq.com)
Several research analysts have recently issued reports on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, June 11th. Cann reiterated a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 18th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $74.75.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) opened at 54.89 on Friday. Agios Pharmaceuticals has a 12-month low of $35.84 and a 12-month high of $67.74. The company has a 50-day moving average price of $57.17 and a 200-day moving average price of $52.32. The firm’s market capitalization is $2.66 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by $0.21. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same period in the prior year, the firm posted ($1.47) earnings per share. The business’s revenue was up 62.1% on a year-over-year basis. Equities analysts predict that Agios Pharmaceuticals will post ($7.07) EPS for the current year.
In related news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the transaction, the director now owns 91,206 shares in the company, valued at approximately $4,295,802.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO David P. Schenkein sold 27,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the transaction, the chief executive officer now owns 3,000 shares in the company, valued at approximately $179,850. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,120 shares of company stock worth $4,557,207. 10.55% of the stock is owned by corporate insiders.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.